Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis

Journal of Bone and Mineral Research

Volumn 26, Issue 1, 2011, Pages 125-134

  Li, Xin ^a   Koh, Amy J ^a   Wang, Zhengyan ^a   Soki, Fabiana N ^a   Park, Serk In ^a   Pienta, Kenneth J ^b   McCauley, Laurie K ^a,b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

APOPTOSIS; MEGAKARYOCYTES; PROSTATE CARCINOMA; SKELETAL METASTASIS

Indexed keywords

CYCLIN D1; DEATH ASSOCIATED PROTEIN KINASE; LIPOCORTIN 5; MESSENGER RNA; RECOMBINANT THROMBOPOIETIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE LESION; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CELL ACTIVITY; CELL GROWTH; CELL INTERACTION; CELL STRAIN K 562; CIRCULATION; COCULTURE; CONTROLLED STUDY; DEATH; FLOW CYTOMETRY; GENE EXPRESSION; HEART TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRECURSOR; PROSTATE CANCER; PROSTATE CARCINOMA;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE NEOPLASMS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEGAKARYOCYTES; MICE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS;

EID: 78650926547     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.204     Document Type: Article

References (41)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10-30.
2. Rubin MA, Putzi M, Mucci N, et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000; 6: 1038-1045.
3. Paget S., The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989; 8: 98-101.
4. Schneider A, Kalikin LM, Mattos AC, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 2005; 146: 1727-1736.
5. Wilson A, Trumpp A., Bone-marrow haematopoietic stem-cell niches. Nat Rev Immunol. 2006; 6: 93-106.
6. Yin T, Li L., The stem cell niches in bone. J Clin Invest. 2006; 116: 1195-1201.
7. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425: 841-846.
8. Lichtman MA, Chamberlain JK, Simon W, Santillo PA., Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. Am J Hematol. 1978; 4: 303-312.
9. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438: 820-827.
10. Liao J, McCauley LK., Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev. 2006; 25: 559-571.
11. Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 1999; 25: 517-523.
12. Ahmed N, Khokher MA, Hassan HT., Cytokine-induced expansion of human CD34+ stem/progenitor and CD34+CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts. Stem Cells. 1999; 17: 92-99.
13. Cheng L, Qasba P, Vanguri P, Thiede MA., Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J Cell Physiol. 2000; 184: 58-69.
14. Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE., Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. Bone. 2005; 36: 812-819.
15. Kacena MA, Gundberg CM, Horowitz MC., A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone. 2006; 39: 978-984.
16. Kacena MA, Nelson T, Clough ME, et al. Megakaryocyte-mediated inhibition of osteoclast development. Bone. 2006; 39: 991-999.
17. Kacena MA, Shivdasani RA, Wilson K, et al. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res. 2004; 19: 652-660.
18. Li X, Loberg R, Liao J, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009; 69: 1685-1692.
19. Mundy GR., Mechanisms of bone metastasis. Cancer. 1997; 80: 1546-1556.
20. Roato I, D'Amelio P, Gorassini E, et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE. 2008; 3: e3627.
21. Shiraga M, Ritchie A, Aidoudi S, et al. Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. J Cell Biol. 1999; 147: 1419-1430.
22. Kalikin LM, Schneider A, Thakur MA, et al. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther. 2003; 2: 656-660.
23. Liao J, Schneider A, Datta NS, McCauley LK., Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 2006; 66: 9065-9073.
24. Jacquel A, Herrant M, Defamie V, et al. A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysis. Oncogene. 2006; 25: 781-794.
25. Czyz M, Szulawska A, Bednarek AK, Duchler M., Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation. Biochem Pharmacol. 2005; 70: 1431-1442.
26. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM., Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005; 5 (Suppl): S46-53.
27. Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat. 2002; 75: 249-258.
28. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879-882. (Pubitemid 38807610)
29. Hirbe AC, Uluckan O, Morgan EA, et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood. 2007; 109: 3424-3431.
30. Palumbo JS, Barney KA, Blevins EA, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008; 6: 812-819.
31. Uluckan O, Eagleton MC, Floyd DH, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem. 2008; 104: 1311-1323.
32. Aksoy S, Kilickap S, Hayran M, et al. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol. 2008; 30: 214-219.
33. Burstein SA., Platelets and cytokines. Curr Opin Hematol. 1994; 1: 373-380.
34. Peng J, Friese P, George JN, Dale GL, Burstein SA., Alteration of platelet function in dogs mediated by interleukin-6. Blood. 1994; 83: 398-403.
35. McConnell BB, Vertino PM., Activation of a caspase-9-mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1. Cancer Res. 2000; 60: 6243-6247.
36. Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS., Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate. 2006; 66: 687-695.
37. Das PM, Ramachandran K, Vanwert J, et al. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer. 2006; 5: 28.
38. Neuhausen A, Florl AR, Grimm MO, Schulz WA., DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther. 2006; 5: 993-1001.
39. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004; 64: 1975-1986.
40. Gray SG, Eriksson T, Ekstrom TJ., Methylation, gene expression and the chromatin connection in cancer. Int J Mol Med. 1999; 4: 333-350.
41. Vaid M, Floros J., Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics ? Oncol Rep. 2009; 21: 3-11.